Joseph Hargett

Joseph Hargett

Despite hailing from the Greater Cincinnati, Ohio area, Joseph Hargett has spent nearly the past decade elbow-deep in Wall Street.  Specializing in financial writing, options strategies and stock-market analysis, Joseph cut his teeth in the research department of Cincinnati-based Schaeffer’s Investment Research.

While at Schaeffer’s, Joseph wrote market, stock and options commentary for SchaeffersResearch.com, and was lead editor for The Options Advisor (the nation’s leading options newsletter).

Joseph has since moved on to become a prolific Forbes contributor in the options realm, as well as a lead copy editor and contributor for a well respected investment newsletter publisher.  Joseph’s commentary has appeared in a plethora of media outlets, including The Wall Street JournalThe New York TimesMoney Show Digest, Reuters, CBE MarketWatch and Sentiment Magazine.

Recent Articles

Wednesday’s Vital Data: Micron Technology, Inc. (MU), Twitter Inc (TWTR) and Bank of America Corp (BAC)

Micron (MU) receives a lowball takeover bid, Twitter (TWTR) rallies on a fake buyout offer and Bank of America (BAC) posts strong earnings.

Netflix Hits Splitsville Ahead of Earnings: 2 Trades for NFLX Stock

Netflix is set to run on potentially strong earnings as the 7-for-1 split opens NFLX stock up to more investors.

Tuesday’s Vital Data: Apple Inc. (AAPL), Facebook Inc (FB) and JPMorgan Chase & Co. (JPM)

Apple (AAPL) was upgraded at Societe Generale, Facebook (FB) was downgraded at Pivotal Research and JPMorgan Chase (JPM) topped earnings estimates.

3 Pre-Earnings Trades: JPM, WFC, BAC

JPMorgan Chase (JPM), Wells Fargo (WFC) and Bank of America (BAC) are set to release earnings amid a shaky global sentiment backdrop. Here are three trades you can make ahead of their upcoming earnings reports.

Monday’s Vital Data: Bank of America Corp (BAC), Netflix, Inc. (NFLX) and AbbVie Inc (ABBV)

Bank of America (BAC) options traders prep for earnings, Netflix (NFLX) draws a bullish brokerage note, AbbVie’s (ABBV) Imbruvica was approved in the EU.